1. Home
  2. TNXP vs PMO Comparison

TNXP vs PMO Comparison

Compare TNXP & PMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • PMO
  • Stock Information
  • Founded
  • TNXP 2007
  • PMO 1993
  • Country
  • TNXP United States
  • PMO United States
  • Employees
  • TNXP N/A
  • PMO N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • PMO Finance Companies
  • Sector
  • TNXP Health Care
  • PMO Finance
  • Exchange
  • TNXP Nasdaq
  • PMO Nasdaq
  • Market Cap
  • TNXP 335.6M
  • PMO 287.4M
  • IPO Year
  • TNXP N/A
  • PMO N/A
  • Fundamental
  • Price
  • TNXP $26.54
  • PMO $10.02
  • Analyst Decision
  • TNXP Buy
  • PMO
  • Analyst Count
  • TNXP 1
  • PMO 0
  • Target Price
  • TNXP $70.00
  • PMO N/A
  • AVG Volume (30 Days)
  • TNXP 1.9M
  • PMO 99.0K
  • Earning Date
  • TNXP 08-11-2025
  • PMO 01-01-0001
  • Dividend Yield
  • TNXP N/A
  • PMO 4.10%
  • EPS Growth
  • TNXP N/A
  • PMO N/A
  • EPS
  • TNXP N/A
  • PMO 0.42
  • Revenue
  • TNXP $9,831,000.00
  • PMO N/A
  • Revenue This Year
  • TNXP $21.19
  • PMO N/A
  • Revenue Next Year
  • TNXP $722.94
  • PMO N/A
  • P/E Ratio
  • TNXP N/A
  • PMO $24.38
  • Revenue Growth
  • TNXP N/A
  • PMO N/A
  • 52 Week Low
  • TNXP $6.76
  • PMO $8.57
  • 52 Week High
  • TNXP $130.00
  • PMO $10.68
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 32.47
  • PMO 64.73
  • Support Level
  • TNXP $34.50
  • PMO $9.80
  • Resistance Level
  • TNXP $29.70
  • PMO $9.91
  • Average True Range (ATR)
  • TNXP 3.35
  • PMO 0.07
  • MACD
  • TNXP -1.55
  • PMO 0.01
  • Stochastic Oscillator
  • TNXP 4.29
  • PMO 100.00

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About PMO Putnam Municipal Opportunities Trust

Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.

Share on Social Networks: